ANI Pharmaceuticals, Inc. $ANIP Holdings Lowered by American Century Companies Inc.

Key Points

• American Century Companies Inc. reduced its stake in ANI Pharmaceuticals by 57.1%, now owning approximately 25,837 shares valued at $1.73 million.
• Insider sales were notable, including Director Jeanne Thoma's sale of 21,540 shares worth nearly $1.92 million, decreasing her position by 47.93%.
• ANI Pharmaceuticals reported a quarterly earnings of $1.80 EPS, which exceeded analysts' expectations by $0.38, alongside a revenue increase of 53.2% year-over-year.

American Century Companies Inc. lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 57.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,837 shares of the specialty pharmaceutical company's stock after selling 34,411 shares during the period. American Century Companies Inc. owned approximately 0.12% of ANI Pharmaceuticals worth $1,730,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ANIP. Millennium Management LLC boosted its stake in shares of ANI Pharmaceuticals by 89.3% in the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock valued at $55,437,000 after purchasing an additional 473,097 shares during the period. Aberdeen Group plc boosted its stake in shares of ANI Pharmaceuticals by 76.1% in the first quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company's stock valued at $28,059,000 after purchasing an additional 181,134 shares during the period. Deep Track Capital LP boosted its stake in shares of ANI Pharmaceuticals by 28.6% in the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after purchasing an additional 144,214 shares during the period. Global Alpha Capital Management Ltd. boosted its stake in shares of ANI Pharmaceuticals by 17.8% in the first quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company's stock valued at $49,248,000 after purchasing an additional 111,040 shares during the period. Finally, GAMMA Investing LLC boosted its stake in shares of ANI Pharmaceuticals by 17,558.4% in the first quarter. GAMMA Investing LLC now owns 95,002 shares of the specialty pharmaceutical company's stock valued at $6,360,000 after purchasing an additional 94,464 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the business's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $86.97, for a total transaction of $1,739,400.00. Following the sale, the senior vice president directly owned 173,226 shares in the company, valued at approximately $15,065,465.22. The trade was a 10.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeanne Thoma sold 21,540 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $89.15, for a total transaction of $1,920,291.00. Following the sale, the director owned 23,405 shares in the company, valued at $2,086,555.75. This trade represents a 47.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 405,538 shares of company stock worth $35,690,131 over the last three months. Insiders own 12.70% of the company's stock.

Wall Street Analyst Weigh In

ANIP has been the subject of several analyst reports. Guggenheim restated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. HC Wainwright reissued a "buy" rating and set a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Zacks Research raised shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 21st. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a report on Monday, August 11th. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $84.75.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock traded up $0.82 during midday trading on Wednesday, reaching $94.92. 523,839 shares of the stock traded hands, compared to its average volume of 739,339. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The firm has a fifty day moving average price of $75.06 and a two-hundred day moving average price of $67.74. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -123.27 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $95.60.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. The firm had revenue of $211.37 million during the quarter, compared to analyst estimates of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. ANI Pharmaceuticals's revenue was up 53.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.02 EPS. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.